FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

When Should Immunocompromised Individuals Receive a COVID Booster?

2.

Older Adults With Advanced Cancer Prioritize Quality of Life

3.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

4.

Can MRI Curb Chemo Overtreatment in Breast Cancer?

5.

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot